Free press releases distribution network?

Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories - Quotient Bioresearch Limited (“Quotient”), a leading provider of drug development services, today announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility
Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories

 

PRZOOM - /newswire/ - Fordham, Cambridgeshire, United Kingdom, 2009/05/18 - Quotient Bioresearch Limited (“Quotient”), a leading provider of drug development services, today announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Quotient Bioresearch Limited (“Quotient”), a leading provider of drug development services, today announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient.

The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new strategic business unit within Quotient - Quotient Clinical.

With a long heritage in early development services, the Charles River Edinburgh clinical unit will combine with Pharmaceutical Profiles to offer a suite of integrated services stretching from First-in-Human (FIH) through to Phase 2a patient studies. Founded almost 20 years ago, the Edinburgh clinical unit is an industry leader in FIH studies. It was awarded Supplementary Accreditation status by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2009, demonstrating its experience and capabilities to conduct FIH trials for small molecules and biologics.

Quotient Clinical will have a workforce of approximately 160 medical, scientific and clinical staff across the two facilities in Edinburgh and Nottingham. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers.

Paul Cowan, Chairman and CEO of Quotient comments, “The creation of Quotient Clinical represents the next step in expanding the range of specialised services we offer pharmaceutical and biotech customers worldwide. We are delighted to have completed the acquisition of the Charles River Edinburgh clinical facility. With the Inveresk heritage we are bringing a world-class facility and clinical experience to Quotient Clinical.”

Quotient Clinical will be headed by Mark Egerton, formerly Chief Executive Officer of Pharmaceutical Profiles. “We will continue to build on the innovative approaches we developed at Pharmaceutical Profiles to increase the effectiveness of early development processes. Combined with the Phase I/2a expertise of the Charles River Edinburgh clinical unit, our approach to integrating flexible drug product manufacture into clinical trials will enable us to deliver significant benefits to our customers.”

For more information on Quotient Clinical, please call +44 (0)115 9749000, email clinical[.]quotientbioresearch.com

About Quotient Bioresearch
Quotient Bioresearch (quotientbioresearch.com) is part of the Quotient Bioscience group. The Quotient Bioscience group comprises Quotient Bioresearch, HFL Sport Science and Alba Bioscience. Quotient Bioresearch provides a range of specialist, early-stage drug development services; HFL Sport Science is the world’s premier drug surveillance and doping control laboratory for sport; and Alba Bioscience is one of the world’s leading manufacturers of monoclonal reagents for blood typing. Quotient Bioscience has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Further acquisitions are anticipated with a view to offering clients a broader, unified range of services.

Media Contacts:
Paul Cowan, Chairman and CEO, Quotient Bioresearch
T: +44 (0)1638 724 500

Mark Egerton, Managing Director, Quotient Clinical
T: +44 (0)115 974 9000

Financial Dynamics
John Dineen/ Ben Atwell T: +44 (0)20 7831 3113

The Scott Partnership
Charlotte Culley/ Sarah Evans T: +44 (0)1477 539539

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sarah Evans 
+44 1477 539539
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  MagLar, Inc.

Visit  RightITnow Ltd

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today